Diabetic Peripheral Neuropathy

If any of the terms on this page are unclear or you want to learn more about them click here!

Diabetic peripheral neuropathy, or DPN, is nerve damage associated with diabetes. The most common form is distal symmetric polyneuropathy: distal means it begins farthest from the center of the body, and symmetric means it usually affects both sides. Symptoms often begin in the toes and feet, then move upward over time. The hands are usually affected only after symptoms have traveled well up the legs, creating a “stocking-and-glove” pattern.

DPN can produce opposite-seeming symptoms. An injured nerve may send too many pain signals, causing burning, electric shocks, stabbing pain, tingling, or extreme sensitivity to a bedsheet. The same nerve may also fail to carry normal signals, causing numbness or loss of temperature, vibration, and position sense. Some people have pain, some have numbness, some have both, and up to half may have no obvious symptoms even when examination shows nerve damage.

Sensory nerves are usually affected first, but motor and autonomic nerves can also be involved. Motor nerve injury can contribute to weakness, altered foot shape, and difficulty lifting the front of the foot. Autonomic nerve injury can disturb sweating, blood pressure, digestion, bladder function, or sexual function. These problems overlap with diabetic autonomic neuropathy, which deserves its own clinical assessment even when a person also has the typical foot-predominant form of DPN.

DPN matters for more than pain. Loss of protective sensation allows a blister, burn, pressure point, or small cut to go unnoticed. Continued walking on an injured area can lead to an ulcer, infection, bone and joint damage called Charcot neuroarthropathy, or amputation. Balance can also worsen because the brain receives less reliable information from the feet. Early recognition therefore aims to protect nerve function, mobility, and the feet in addition to reducing discomfort.

Pathology

The central pathological feature of typical DPN is length-dependent axon loss. Axons are the long extensions of nerve cells that carry signals between the spinal cord and the skin, muscles, and organs. The axons reaching the toes can be several feet long, so their farthest ends have unusually high demands for energy, maintenance, and transport. When diabetes disrupts those support systems, the ends of the longest axons are often the first to fail.

Small and large nerve fibers contribute different functions. Thin small fibers carry pain and temperature signals and help control sweating and small blood vessels. Their injury can cause burning pain, abnormal temperature sensation, dry or cracked skin, and symptoms even when routine nerve-conduction studies are normal.

Schwann cells form myelin, the insulating layer around many peripheral axons, and also provide metabolic support to axons. Diabetes can disturb both the axon and its surrounding Schwann cells. Larger myelinated fibers carry vibration and position information and help coordinate movement. Their loss contributes to numbness, absent ankle reflexes, poor balance, and reduced awareness of where the feet are in space. Nerve biopsies and other studies commonly show axon loss, attempted regeneration, changes in myelin, and injury to the nerve’s smallest blood vessels. However, DPN is not caused by one uniform lesion. Neurons, Schwann cells, immune cells, and the small blood vessels can all contribute, and their relative importance may differ between type 1 and type 2 diabetes.

Biological Pathways

Chronic high glucose is an important driver, but DPN is better understood as a combined metabolic and vascular injury than as “sugar coating the nerves.” Excess glucose enters pathways that consume cellular resources and produce damaging byproducts. The polyol pathway converts glucose to sorbitol, advanced glycation end products alter proteins and blood vessels, and several stress pathways increase reactive oxygen species. Together these changes strain mitochondria, the organelles that supply energy to axons.

Abnormal blood fats and impaired insulin signaling also matter, especially in type 2 diabetes. Excess fatty acids and oxidized lipids can injure mitochondria, cell membranes, and the endoplasmic reticulum, which helps cells fold proteins. Obesity, high triglycerides, and other features of metabolic syndrome can add to nerve stress even when a single glucose measurement looks acceptable. This helps explain why glucose control has a stronger preventive effect in type 1 diabetes than in type 2 diabetes, where several metabolic risks often act together.

Inflammation can amplify this injury. Metabolic signals activate macrophages and other immune pathways around nerves and in fat tissue. Inflammatory molecules can alter ion channels, sensitize pain fibers, and interfere with repair. The result is not the same as an autoimmune neuropathy, but chronic low-grade inflammation can make metabolically stressed nerves less resilient.

Progression

DPN usually develops gradually. Early injury may affect small fibers first, producing burning, tingling, altered temperature sensation, or pain while strength, reflexes, and standard nerve-conduction studies remain relatively normal. With continuing injury, numbness spreads upward, ankle reflexes diminish, vibration and position sense decline, and balance becomes less reliable. Weakness is generally a later and less prominent feature of typical DPN.

The course is variable. Some people remain stable for years, especially when diabetes and other cardiovascular risks are well managed. Others slowly lose sensation and mobility. Once many axons have been lost, recovery is limited because peripheral axons regrow slowly and may need to travel a long distance to reconnect with the foot. Treatment can still reduce further injury and complications even when established numbness does not disappear.

Pain can change independently of numbness. It may improve, fluctuate, or become less noticeable as sensory fibers are lost; less pain does not necessarily mean the nerve is healthier. A painless foot can actually be at greater risk because injuries are easier to miss. Regular examination remains important even when symptoms seem mild.

Causes

The direct cause of DPN is diabetes, but risk depends on the amount and duration of metabolic stress and on the nerve’s underlying resilience. Longer diabetes duration and greater cumulative exposure to high glucose are consistent risks. Older age, greater height, kidney disease, smoking, high blood pressure, obesity, abnormal blood fats, and cardiovascular disease have also been associated with DPN in different populations.

In type 1 diabetes, long-term evidence from the DCCT/EDIC study shows that intensive glucose management lowers the risk of DPN. A 2020 DCCT/EDIC analysis found that long-term average HbA1c was the strongest measured risk factor, followed by factors including age, diabetes duration, height, and kidney involvement. In type 2 diabetes, glucose control remains important, but weight, lipids, blood pressure, smoking, exercise, sleep, and other cardiometabolic factors deserve attention because glucose lowering alone offers only partial protection.

Treatment Landscape

There is currently no medication proven to restore nerve fibers lost to established DPN. Treatment has four connected goals: reduce ongoing nerve injury, protect the feet, preserve strength and balance, and control pain enough to improve sleep and daily function.

Glucose management should be individualized. Consistent control clearly helps prevent or slow DPN in type 1 diabetes and is part of comprehensive care in type 2 diabetes. Avoiding repeated severe highs and lows may be as important to day-to-day function as reaching a particular average. Blood pressure, cholesterol and triglycerides, kidney health, smoking, nutrition, weight, sleep, and physical activity should be addressed alongside glucose.

Exercise can improve fitness, balance, strength, insulin sensitivity, and mobility. A 2021 review promising effects of aerobic, resistance, balance, and combined training, while also noting that studies use different programs and outcomes. Exercise should be matched to foot sensation, ulcer risk, heart health, and baseline ability.

Pain treatment is chosen by medication class, side effects, other illnesses, sleep, mood, fall risk, kidney function, and cost. Options include serotonin-norepinephrine reuptake inhibitors such as duloxetine, gabapentinoids such as pregabalin or gabapentin, tricyclic antidepressants, and certain sodium-channel blockers. Topical lidocaine or prescription-strength capsaicin may help pain limited to a defined area. These treatments reduce abnormal pain signaling; they do not repair the underlying nerve. No single pain medicine works for everyone, and complete pain relief is uncommon. For severe painful DPN that has not responded to appropriate medication trials, selected patients may be evaluated for neuromodulation.

Research Directions

The largest unmet need is a disease-modifying treatment that protects or repairs nerves rather than only treating pain. Researchers are testing strategies aimed at mitochondrial function, lipid metabolism, inflammation, oxidative stress, the polyol pathway, ion channels, Schwann-cell support, and axon-degeneration pathways such as SARM1. The challenge is that DPN is biologically diverse: a treatment that helps one stage or metabolic profile may not help another.

Researchers are also trying to match pain treatment to mechanism. Pain questionnaires, sensory profiles, genetics, skin innervation, brain imaging, and digital measures may eventually identify subgroups more likely to respond to a particular medication or device. Better trials will need to measure not only pain intensity but also sleep, walking, balance, foot outcomes, participation, and quality of life.

Finally, prevention research is shifting from glucose alone to whole-person metabolic health. Combining durable glucose management with exercise, weight and lipid treatment, smoking cessation, vascular protection, and early foot care may offer more benefit than any one intervention, particularly in type 2 diabetes.

Sources

American Diabetes Association Professional Practice Committee for Diabetes. (2026). “Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026.”
Masha G. Savelieff et al. (2025). “The Global and Regional Burden of Diabetic Peripheral Neuropathy.”
Melissa A. Elafros et al. (2022.) “Towards Prevention of Diabetic Peripheral Neuropathy: Clinical Presentation, Pathogenesis, and New Treatments.”
Gordon Sloan, Dinesh Selvarajah, and Solomon Tesfaye. (2021). “Pathogenesis, Diagnosis and Clinical Management of Diabetic Sensorimotor Peripheral Neuropathy.”
Eva L. Feldman et al. (2019). “Diabetic Neuropathy.”
Roy Price et al. (2022). “Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary.”
Barbara H. Braffett et al. (2020). “Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the DCCT/EDIC Study.”
Clifton J. Holmes and Mary K. Hastings. (2021). “The Application of Exercise Training for Diabetic Peripheral Neuropathy.”
Erika A. Petersen et al. (2021). “Effect of High-Frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial.”
Yo Sasaki et al. (2020). “cADPR Is a Gene Dosage-Sensitive Biomarker of SARM1 Activity in Healthy, Compromised, and Degenerating Axons.”
Y. Cheng et al. (2019). “Sarm1 Gene Deficiency Attenuates Diabetic Peripheral Neuropathy in Mice.”

CMT / Peripheral Neuropathy

SARMopathy

Inflammation